Frontiers in Pentadecapeptide BPC 157: Volume II

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 10298

Special Issue Editor


E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

This Special Issue deals with pentadecapeptide BPC 157, a native gastric peptide that is resistant and stable in the human gastric juice; it is a membrane stabilizer and counteracts leaky-gut syndrome. This stable gastric peptide is a particular target distinctive from the standard peptide growth factors, with particular molecular pathways involved, controlling VEGF and NO pathways. In the early 1990s, pentadecapeptide BPC 157 appeared as a late outbreak of Robert’s and Szabo’s cytoprotection/organoprotection concept, and from previous theoretical/practical breakthroughs in the 1980s on the gut–brain axis; over time, with its reported effects, likely most useful confirmation of theory in practical implementation and justification. Against various noxious agents causing direct cell injury, the epithelial and endothelial integrity maintenance in the stomach (cytoprotection) and in the other tissues (organoprotection) was not fully realized with the standard cytoprotective agents (i.e., prostaglandins, before sulfhydrils, CRF, EGF, somatostatin, and dopamine agonists) acting through cytoprotective defensive systems. As novel mediator, BPC 157 was coming after the evidenced point of their limited beneficial effects, and NO-system importance widely introduced, but vigorously established interconnection with these important systems (i.e., prostaglandins, dopamine, serotonin, NO). Thereby, BPC 157 therapy has a pleiotropic beneficial effect. In addition to the beneficial effect on the entire gastrointestinal tract, and other organs various agents- and/or noxious procedures-induced lesions (liver (cirrhosis), lung, heart, spinal cord and brain), and considerable wound healing (i.e., skin, muscle, tendon, ligament, bone) (and especial wound, i.e., corneal ulcer), it may include counteraction of the depression-models, schizophrenia positive symptom models and catalepsy models. Recently, BPC 157 has been shown to counteract vascular occlusion disturbances and blood pressure disturbances (relieving Virchow's triad (endothelium lesions, hypercoagulability, stasis) by the rapid activation of collateral vessel pathways.

Prof. Dr. Predrag S. Sikirić
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cytoprotection
  • gastric pentadecapeptide BPC 157
  • peptides, healing
  • tissues lesions
  • blood vessels lesions
  • wounds
  • brain-gut axis
  • inflammation and resolution
  • cancer prevention
  • therapy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1112 KiB  
Article
Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
by Ozren Gamulin, Katarina Oroz, Luka Coric, Maria Krajacic, Marko Skrabic, Vilim Dretar, Sanja Strbe, Jasminka Talapko, Martina Juzbasic, Ivan Krezic, Marin Lozic, Vasilije Stambolija, Helena Zizek, Ivana Jurca, Ivana Jurjevic, Alenka Boban Blagaic, Anita Skrtic, Sven Seiwerth and Predrag Sikiric
Biomedicines 2022, 10(12), 3130; https://doi.org/10.3390/biomedicines10123130 - 4 Dec 2022
Cited by 10 | Viewed by 1897
Abstract
Recently, it was found that when confronted with major vessel occlusion and vascular failure, stable gastric pentadecapeptide BPC 157 therapy might rapidly functionally improve minor vessels to take over the function of disabled major vessels, reorganize blood flow, and compensate failed vessel function. [...] Read more.
Recently, it was found that when confronted with major vessel occlusion and vascular failure, stable gastric pentadecapeptide BPC 157 therapy might rapidly functionally improve minor vessels to take over the function of disabled major vessels, reorganize blood flow, and compensate failed vessel function. We focused on the BPC 157 therapy effect obtained by giving 10 ng/kg ip to rats 5 min before sacrifice on the rat thoracic aorta, which we assessed with Fourier transform infrared spectroscopy (FTIR) 90 min thereafter. We applied a principal component analysis (PCA). The PCA model showed, with a clear distinction being mostly due to the PC1 score, differences between the spectra of BPC 157- and saline-treated rats. The comparison of the averaged spectra of these two groups with their differential spectrum and PC loadings allowed us to identify the parts of the FTIR spectra that contributed the most to the spectral separation of the two observed groups. The PC1 loadings and the differential spectrum showed that the main bands affecting the separation were the amid I band around 1650 cm−1, the amid II band around 1540 cm−1, and the vibrational band around 1744 cm−1. Fitting the spectral range between 1450 and 1800 cm−1 showed changes in protein conformation and confirmed the appearance of the vibrational band at 1744 cm−1. Controls had a substantially more intense vibrational band at 1744 cm−1. These spectral results showed the cells from saline-treated (control) rats to be in the early stage of cell death, while the samples from BPC 157-rats were protected. Thus, BPC 157 therapy changed the lipid contents and protein secondary structure conformation, with a rapid effect on vessels, within a short time upon application. Full article
(This article belongs to the Special Issue Frontiers in Pentadecapeptide BPC 157: Volume II)
Show Figures

Figure 1

Review

Jump to: Research

40 pages, 6724 KiB  
Review
Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle
by Mario Staresinic, Mladen Japjec, Hrvoje Vranes, Andreja Prtoric, Helena Zizek, Ivan Krezic, Slaven Gojkovic, Ivan Maria Smoday, Katarina Oroz, Eva Staresinic, Vilim Dretar, Haidi Yago, Marija Milavic, Suncana Sikiric, Eva Lovric, Lovorka Batelja Vuletic, Paris Simeon, Ivan Dobric, Sanja Strbe, Antonio Kokot, Josipa Vlainic, Alenka Boban Blagaic, Anita Skrtic, Sven Seiwerth and Predrag Sikiricadd Show full author list remove Hide full author list
Biomedicines 2022, 10(12), 3221; https://doi.org/10.3390/biomedicines10123221 - 12 Dec 2022
Cited by 10 | Viewed by 8147
Abstract
First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective [...] Read more.
First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury. As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability to organize simultaneous healing of different tissues of and full recovery of the myotendinous junction might represent the particular muscle therapy against distinctive etiopathology muscle disabilities and weakness. In this, BPC 157 therapy might recover many of muscle disabilities (i.e., succinylcholine, vascular occlusion, spinal cord compression, stroke, traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome and NO-system blockade and tumor-cachexia). These might provide practical realization of the multimodal muscle-axis impact able to react depending on the condition and the given agent(s) and the symptoms distinctively related to the prime injurious cause symptoms in the wide healing concept, the concept of cytoprotection, in particular. Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (µg-ng regimens) and ways of application). Full article
(This article belongs to the Special Issue Frontiers in Pentadecapeptide BPC 157: Volume II)
Show Figures

Figure 1

Back to TopTop